SRRK:NASDAQ, Scholar Rock Holding Corporation
SRRK stock overview
Scholar Rock Holding Corporation (SRRK:NASDAQ) closed at $39.90 on October 16, 2026,
down 1.82% on the day.
The stock trades 35.4% below its 52-week high of $61.76
and 47.4% above its 52-week low of $27.07.
Over the past year, it gained 38.0%.
Scholar Rock Holding Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
Key figures
- Price
- $39.90
- Day change
- -1.82%
- Volume
- 2,893,997
- Average volume
- 1,559,159
- Market cap
- 4B+
- 52-week range
- $27.07 – $61.76
- 50-day average
- $50.95
- 200-day average
- $48.27
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -3.10% |
-17.68% |
-19.78% |
-14.98% |
+38.04% |
Price action over the past year
In 252 trading sessions since October 16, 2025, SRRK closed higher on 122 days (48%).
Its best day was November 14, 2025 (+24.41%) and its worst was October 16, 2025 (-9.14%).
The stock moved 10% or more in a single session 3 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
SRRK news
-
Oct 16, 2026:
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
-
Oct 8, 2026:
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
-
Oct 2, 2026:
3 drug targets pharma is betting on next
-
Sep 28, 2026:
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
-
Sep 25, 2026:
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
-
Sep 21, 2026:
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sep 18, 2026:
This week in charts: GSK's China deals, the $300M IPO club and selling the news
-
Sep 18, 2026:
This week in charts: GSKs China deals, the $300M IPO club and selling the news
About Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia.
Similar stocks
Find more stocks like SRRK with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.